Please wait while the formulary information is being retrieved.
SYLATRON (PEGINTERFERON ALFA-2B)
- Adjuvant treatment of melanoma
200 mcg subcutaneous kit
- Inject 3 mcg/kg by subcutaneous route once weekly
300 mcg subcutaneous kit
- Inject 3 mcg/kg by subcutaneous route once weekly
600 mcg subcutaneous kit
- Inject 3 mcg/kg by subcutaneous route once weekly
200 mcg subcutaneous kit
- Inject 3 mcg/kg by subcutaneous route once weekly
300 mcg subcutaneous kit
- Inject 3 mcg/kg by subcutaneous route once weekly
600 mcg subcutaneous kit
- Inject 3 mcg/kg by subcutaneous route once weekly
Adjuvant treatment of melanoma
- Inject 6 mcg/kg by subcutaneous route once weekly
- Inject 6 mcg/kg by subcutaneous route once weekly for 8 weeks
- Inject 3 mcg/kg by subcutaneous route once weekly
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Droxia
- Fazaclo
- Ferriprox
- Hydrea
- hydroxyurea
- Versacloz
Severe
Moderate
- colchicine
- colchicine-probenecid
- Colcrys
- erlotinib
- Tarceva
- Acute pancreatitis
- Autoimmune hepatitis
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Hemorrhagic colitis
- Hepatic failure
- Ischemic colitis
- Sickle cell disease
- Thalassemia
- Ulcerative colitis
Contraindicated
- Acute myocardial infarction
- Aplastic anemia
- Autoimmune disease
- Bipolar disorder
- Cardiac arrhythmia
- Cerebrovascular accident
- Depression
- Diabetic retinopathy
- Drug dependence
- Hepatic cirrhosis
- Homicidal ideation
- Hypertensive retinopathy
- Hyperthyroidism
- Hypothyroidism
- Kidney disease with reduction in GFR
- Manic disorder
- Papilledema
- Psychotic disorder
- Pulmonary infiltrates
- Recipient of organ transplant
- Severe anemia
- Severe infection
- Severe neutropenic disorder
- Severe thrombocytopenia
- Suicidal ideation
Severe
Moderate
- Anemia
- Diabetes mellitus
- Hypertriglyceridemia
- Kidney disease with likely reduction in GFR
- Periodontitis
- Pulmonary disease
SYLATRON (PEGINTERFERON ALFA-2B)
- Adjuvant treatment of melanoma
- Abnormal hepatic function tests
- Depression
- Irritability
- Mood changes
- Alopecia
- Anorexia
- Arthralgias
- Chills
- Diarrhea
- Dizziness
- Dysgeusia
- Exfoliative dermatitis
- Fatigue
- Fever
- Flu-like symptoms
- Headache disorder
- Injection site sequelae
- Myalgias
- Nausea
- Paresthesia
- Parosmia
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Anemia
- Dyspnea
- Hypothyroidism
- Peripheral neuropathy
- Cough
- Proteinuria
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Aggressive behavior
- Anaphylaxis
- Angina
- Angioedema
- Bronchospastic pulmonary disease
- Bundle branch block
- Cardiac arrhythmia
- Cardiomyopathy
- Cerebrovascular accident
- Colitis
- Diabetes mellitus
- Encephalopathy
- Erythema multiforme
- Hearing loss
- Homicidal ideation
- Hypersensitivity drug reaction
- Hypertension
- Hyperthyroidism
- Hypertriglyceridemia
- Hypotension
- Infection
- Interstitial nephritis
- Interstitial pneumonitis
- Kidney disease with reduction in GFR
- Macular retinal edema
- Manic disorder
- Migraine
- Myositis
- Optic neuritis
- Pancreatitis
- Pericarditis
- Pneumonia
- Psoriasis
- Psychiatric disorder
- Pulmonary fibrosis
- Pulmonary hypertension
- Pulmonary infiltrates
- Pure red cell aplasia
- Reactivation of hepatitis B
- Retinal detachment
- Retinal disorder
- Retinal thrombosis
- Rhabdomyolysis
- Rheumatoid arthritis
- Sarcoidosis
- Seizure disorder
- Stevens-johnson syndrome
- Suicidal
- Suicidal ideation
- Systemic lupus erythematosus
- Thrombotic thrombocytopenic purpura
- Thyroiditis
- Toxic epidermal necrolysis
- Urticaria
- Uveitis
- Vision loss
- Vogt-koyanagi-harada disease
Less Severe
- Aphthous stomatitis
- Bronchiolitis
- Dehydration
- General weakness
- Malaise
- Palpitations
- Papilledema
- Tongue discoloration
- Vertigo
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Peginterferon Alfa-2b
Growth inhibition reported in combination with ribavirin. Safety and efficacy not established in pediatrics age < 3 years.
May affect growth rate and weight gain. Monitor for depression and changes in behavior using recommended dose adjustment guidelines.
- 1 Day – 3 Years
- Growth inhibition reported in combination with ribavirin. Safety and efficacy not established in pediatrics age < 3 years.
- May affect growth rate and weight gain. Monitor for depression and changes in behavior using recommended dose adjustment guidelines.
- 3 Years – 18 Years
- Growth inhibition reported in combination with ribavirin. Safety and efficacy not established in pediatrics age < 3 years.
- May affect growth rate and weight gain. Monitor for depression and changes in behavior using recommended dose adjustment guidelines.
Peginterferon Alfa-2B
- Severity Level:
2
- Additional Notes: Insufficient human data; animal data sug dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Peginterferon Alfa-2B
Insufficient data available; large mw; infant oral absorption unlikely
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available; large mw; infant oral absorption unlikely |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Peginterferon alfa-2b may cause you to develop serious mental/mood changes during treatment and up to 6 months after your last dose of the medication. Tell your doctor right away if you have symptoms such as confusion, depression, thoughts of suicide or hurting others, unusual irritability, or aggressive behavior. Your doctor may recommend psychiatric therapy and monitoring.<br /><br />Treatment with this medication may be stopped if symptoms are severe. However, these symptoms may not go away even after stopping the medication.
| Adjuvant treatment of melanoma | |
| C43 | Malignant melanoma of skin |
| C43.0 | Malignant melanoma of lip |
| C43.1 | Malignant melanoma of eyelid, including canthus |
| C43.10 | Malignant melanoma of unspecified eyelid, including canthus |
| C43.11 | Malignant melanoma of right eyelid, including canthus |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.12 | Malignant melanoma of left eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.2 | Malignant melanoma of ear and external auricular canal |
| C43.20 | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.3 | Malignant melanoma of other and unspecified parts of face |
| C43.30 | Malignant melanoma of unspecified part of face |
| C43.31 | Malignant melanoma of nose |
| C43.39 | Malignant melanoma of other parts of face |
| C43.4 | Malignant melanoma of scalp and neck |
| C43.5 | Malignant melanoma of trunk |
| C43.51 | Malignant melanoma of anal skin |
| C43.52 | Malignant melanoma of skin of breast |
| C43.59 | Malignant melanoma of other part of trunk |
| C43.6 | Malignant melanoma of upper limb, including shoulder |
| C43.60 | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.61 | Malignant melanoma of right upper limb, including shoulder |
| C43.62 | Malignant melanoma of left upper limb, including shoulder |
| C43.7 | Malignant melanoma of lower limb, including hip |
| C43.70 | Malignant melanoma of unspecified lower limb, including hip |
| C43.71 | Malignant melanoma of right lower limb, including hip |
| C43.72 | Malignant melanoma of left lower limb, including hip |
| C43.8 | Malignant melanoma of overlapping sites of skin |
| C43.9 | Malignant melanoma of skin, unspecified |
| 0-9 | A-Z |
|---|---|
| C43 | Malignant melanoma of skin |
| C43.0 | Malignant melanoma of lip |
| C43.1 | Malignant melanoma of eyelid, including canthus |
| C43.10 | Malignant melanoma of unspecified eyelid, including canthus |
| C43.11 | Malignant melanoma of right eyelid, including canthus |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.12 | Malignant melanoma of left eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.2 | Malignant melanoma of ear and external auricular canal |
| C43.20 | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.3 | Malignant melanoma of other and unspecified parts of face |
| C43.30 | Malignant melanoma of unspecified part of face |
| C43.31 | Malignant melanoma of nose |
| C43.39 | Malignant melanoma of other parts of face |
| C43.4 | Malignant melanoma of scalp and neck |
| C43.5 | Malignant melanoma of trunk |
| C43.51 | Malignant melanoma of anal skin |
| C43.52 | Malignant melanoma of skin of breast |
| C43.59 | Malignant melanoma of other part of trunk |
| C43.6 | Malignant melanoma of upper limb, including shoulder |
| C43.60 | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.61 | Malignant melanoma of right upper limb, including shoulder |
| C43.62 | Malignant melanoma of left upper limb, including shoulder |
| C43.7 | Malignant melanoma of lower limb, including hip |
| C43.70 | Malignant melanoma of unspecified lower limb, including hip |
| C43.71 | Malignant melanoma of right lower limb, including hip |
| C43.72 | Malignant melanoma of left lower limb, including hip |
| C43.8 | Malignant melanoma of overlapping sites of skin |
| C43.9 | Malignant melanoma of skin, unspecified |
Formulary Reference Tool